Your session is about to expire
← Back to Search
Baricitinib for Pyoderma Gangrenosum
Study Summary
This trial is testing the effectiveness of the drug baricitinib for the treatment of pyoderma gangrenosum.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 1307 Patients • NCT01710358Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the Food and Drug Administration's thoughts on Baricitinib?
"There is some supporting data for the safety of Baricitinib, but none for efficacy, so it received a score of 2."
Does the age limit for this clinical trial exclude people over 50 years old?
"This study's age requirements for participants are between 18 to 99 years old."
Could you please tell us what other research studies have been conducted using Baricitinib?
"There are currently 34 clinical trials underway that are studying the effects of Baricitinib. Out of those, 17 have reached Phase 3. Pune, Maharashtra has the most active studies for this medication with 17 taking place. However, there are a total of 1439 locations running these sorts of investigations."
Are we still looking for individuals to participate in this research?
"The study is still open and recruiting patients, as evidenced by the information on clinicaltrials.gov. The trial was originally posted on September 29th, 2021 and updated for the last time on August 30th, 2022."
What are the primary benefits of taking Baricitinib?
"Baricitinib has potential as a treatment for hospitalized patients. Additionally, it is being trialed as a possible intervention for coronavirus disease 2019 (covid‑19), ecmo treatment, and rheumatoid arthritis."
What goals does this experiment aim to achieve?
"The primary outcome of this trial will be evaluated over a Measured at week 0, 2, 6, 8, 12, 24. time frame and is to Healing. Secondary outcomes include Percent change in lesion surface area which is defined as The percent change in surface area of target lesion of PG (two-dimensional surface in cm²) using digital photography and acetate tracing at Week 0 and Week 24, Mean change in Physician Global Assessment (PGA) which is defined as The mean change in Physician global assessment (PGA) 5-point scale at week 0 to week 24, and Physician Global Assessment"
How many individuals are part of this research project?
"This is accurate. The trial, which was posted on September 29th 2021 and updated August 30th 2022, as indicated by clinicaltrials.gov, is currently looking for 20 patients from 1 location."
Might I be able to join this experiment?
"This trial is looking for 20 patients with pyoderma gangrenosum who meet the following criteria: -Willingness to comply with study procedures and requirements -Capable of giving informed consent -Diagnosis of at least one PG ulcer by clinical, histological, and laboratory assessments with a minimum wound size of 4 cm2. -Male age 18-99 who agree to not father a child or donate sperm while on study and at least 1 week following the last dose of the study drug; if subject is sexually active male and could cause a pregnancy, subject must be"
Share this study with friends
Copy Link
Messenger